DLA Piper advised Parnell Pharmaceuticals Holdings Ltd (PARN) in its initial public offering on the NASDAQ. PARN, an Australian-based veterinary pharmaceutical company with US operations located in Kansas City, Kansas, focuses on developing, manufacturing and commercializing innovative animal health solutions. The company currently markets five products for companion animals and production animals in 14 countries and augments its pharmaceutical products with its proprietary software platforms.

The international DLA Piper team leading this cross-border offering included Andrew Gilbert, David Schwartz and Kirsten O’Donnell in New Jersey; Julia Kovacs and Linda Thomas in Baltimore; Michael Greenberg in New York; Rita Patel in Washington, DC; David Morris, Simone Mitchell and Leah O’Brien in Sydney; and James Newnham in Melbourne.